Acute Kidney Injury: Management and Prevention

  • Yogita Aggarwal
  • Mark Harber
  • Christopher M. Laing


Until relatively recently, and somewhat to the discredit of nephrology, the management of AKI has been rather a Cinderella subject breeding a nihilistic approach to both the treatment and importance of this common phenomenon. However, overwhelming data demonstrating the high mortality associated with developing AKI, and that AKI predisposes to CKD, have spawned intense interest in AKI and approaches to safely manage patients who develop it. There is now a welter of very good clinical guidelines including 2012 KDIGO [1] NICE [2], intensive care society ( and the National Confidential Enquiry into patient outcome and death ‘Adding Insult to Injury’ [3]. The London AKI Network has produced pragmatic and practical guidelines covering the care bundle for the management of patients with AKI which can be modified to suit local practice [4] ( and London AKI app). Imaginative, novel and inspirational approaches are being developed to foster AKI networks harmonising protocols, audit and overall patient care. The challenge for nephrologists is to raise the profile of AKI and implement systems and training that support the prevention and rapid treatment of all patients with AKI.


Renal Replacement Therapy Urine Output Continuous Renal Replacement Therapy Hydroxyethyl Starch Intermittent Haemodialysis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    NICE. KDIGO Clinical Practice Guideline for Acute Kidney Injury 2013.
  2. 2.
  3. 3.
    National Confidential Enquiry into Patient Outcome and Death. Adding insult to injury. 2009.
  4. 4.
  5. 5.
    Levey AS. The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. Kidney Int. 2011;80:17–28.
  6. 6.
    Thakar CV, Arrigain S, Worley S, et al. A clinical score to predict acute renal failure after cardiac surgery. J Am Soc Nephrol. 2005;16(1):162–8.PubMedGoogle Scholar
  7. 7.
    Evenpoel P. Acute toxin renal failure. Best Pract Res Clin Anaesthesiol. 2004;18:37–52.CrossRefGoogle Scholar
  8. 8.
    Kelly AM, Dwamena B, Cronin P, et al. Meta-analysis: effectiveness of drugs for preventing contrast-induced nephropathy. Ann Intern Med. 2008;148:284–94.PubMedCrossRefGoogle Scholar
  9. 9.
    Merten GJ, Burgess WP, Gray LV. Prevention of contrast-induced nephropathy with sodium bicarbonate: a randomized controlled trial. JAMA. 2004;291:2328–34.PubMedCrossRefGoogle Scholar
  10. 10.
    Jang J-S. Sodium bicarbonate therapy for the prevention of contrast-induced acute kidney injury – a systematic review and meta-analysis. Circ J. 2012;76:2255–65.PubMedCrossRefGoogle Scholar
  11. 11.
    Tepel M. Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med. 2000;343:180–4.PubMedCrossRefGoogle Scholar
  12. 12.
    Chousterman BG, Bouadma L, Moutereau S, et al. Prevention of contrast-induced nephropathy by N-acetylcysteine in critically ill patients: different definitions, different results. J Crit Care. 2013;28:701–9. pii:S0883-9441(13)00068-3.PubMedCrossRefGoogle Scholar
  13. 13.
    Brown JR. Sodium bicarbonate plus N-acetylcysteine prophylaxis: a meta-analysis. JACC Cardiovasc Interv. 2009;2:1116–24.PubMedCrossRefGoogle Scholar
  14. 14.
    McGuiness SP, Parke RL, Bellomo R, et al. Sodium bicarbonate infusion to reduce cardiac surgery–associated acute kidney injury: a phase II multicenter double-blind randomized controlled trial. Crit Care Med. 2013;41:1599–607.CrossRefGoogle Scholar
  15. 15.
    Paul M. Beta lactam antibiotic monotherapy versus beta lactam-aminoglycoside antibiotic combination therapy for sepsis. Cochrane Database Syst Rev. 2006;25(1):CD003344.Google Scholar
  16. 16.
    Nicolau DP. American society for microbiology experience with a once-daily aminoglycoside program administered to 2,184 adult patients. Antimicrob Agents Chemother. 1995;39(3):650–5.PubMedCentralPubMedCrossRefGoogle Scholar
  17. 17.
    Zahar JR. Inappropriate prescribing of aminoglycosides: risk factors and impact of an antibiotic control team. J Antimicrob Chemother. 2006;58:651–6.PubMedCrossRefGoogle Scholar
  18. 18.
    Ashley C, Currie A. The renal drug handbook. 3rd ed. Oxford: Addition Radcliffe Medical Press; 2008.Google Scholar
  19. 19.
    Dellinger RP. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med. 2013;41:580–637.PubMedCrossRefGoogle Scholar
  20. 20.
    Rivers E, et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med. 2001;345:1368–77.PubMedCrossRefGoogle Scholar
  21. 21.
    Daniels R, et al. The sepsis six and the severe sepsis resuscitation bundle: a prospective observational cohort study. Emerg Med J. 2011;28(6):507–12.PubMedCrossRefGoogle Scholar
  22. 22.
    Bouchard J. Fluid accumulation, survival and recovery of kidney function in critically ill patients with acute kidney injury. Kidney Int. 2009;76:422–7.PubMedCrossRefGoogle Scholar
  23. 23.
    Boyd JH, Forbes J, Nakada TA, et al. Fluid resuscitation in septic shock: a positive fluid balance and elevated central venous pressure are associated with increased mortality. Crit Care Med. 2011;39(2):259–65.PubMedCrossRefGoogle Scholar
  24. 24.
    Payen D. A positive fluid balance is associated with a worse outcome in patients with acute renal failure. Crit Care. 2008;12:R74.PubMedCentralPubMedCrossRefGoogle Scholar
  25. 25.
    Wiedermann CJ. Systematic review of randomized clinical trials on the use of hydroxyethyl starch for fluid management in sepsis. BMC Emerg Med. 2008;8:1.PubMedCentralPubMedCrossRefGoogle Scholar
  26. 26.
    Perner A, Haase N, Guttormsen AB, et al., 6S Trial Group, Scandinavian Critical Care Trials Group. Hydroxyethyl starch 130/0.42 versus Ringer’s acetate in severe sepsis. N Engl J Med. 2012;367:124–34.Google Scholar
  27. 27.
    Myburgh JA, Finfer S, Bellomo R, CHEST Investigators; Australian and New Zealand Intensive Care Society Clinical Trials Group, et al. Hydroxyethyl starch or saline for fluid resuscitation in intensive care. N Engl J Med. 2012;367:1901–11.PubMedCrossRefGoogle Scholar
  28. 28.
    Perel P, Roberts I. Colloids versus crystalloids for fluid resuscitation in critically ill patients. Cochrane Database Syst Rev. 2011;(3):CD000567.Google Scholar
  29. 29.
    Delaney AP, Dan A, McCaffrey J, et al. The role of albumin as a resuscitation fluid for patients with sepsis: a systematic review and meta- analysis. Crit Care Med. 2011;39:386–91.PubMedCrossRefGoogle Scholar
  30. 30.
    Finfer S, Bellomo R, Boyce N, SAFE Study Investigators, et al. A comparison of albumin and saline for fluid resuscitation in the intensive care unit. N Engl J Med. 2004;350:2247–56.PubMedCrossRefGoogle Scholar
  31. 31.
    Martin C, Viviand X, Leone M, et al. Effect of norepinephrine on the outcome of septic shock. Crit Care Med. 2000;28:2758–65.Google Scholar
  32. 32.
    Patel GP, Grahe JS, Sperry M, et al. Efficacy and safety of dopamine versus norepinephrine in the management of septic shock. Shock. 2010;33:375–80.PubMedCrossRefGoogle Scholar
  33. 33.
    Bellomo R, Chapman M, Finfer S, et al. Low-dose dopamine in patients with early renal dysfunction: A placebo-controlled randomised trial. Australian and New Zealand Intensive Care Society (ANZICS) Clinical Trials Group. Lancet. 2000;356:2139–43.PubMedCrossRefGoogle Scholar
  34. 34.
    Kellum JA, M Decker J. Use of dopamine in acute renal failure: a meta-analysis. Crit Care Med. 2001;29:1526–31.PubMedCrossRefGoogle Scholar
  35. 35.
    Scharman EJ. Prevention of kidney injury following rhabdomyolysis: a systematic review. [Review]. Ann Pharmacother. 2013;47(1):90–105. UI: 23324509.PubMedCrossRefGoogle Scholar
  36. 36.
    Perazella MA. Crystal-induced acute renal failure. Am J Med. 1999;106(4):459–65.PubMedCrossRefGoogle Scholar
  37. 37.
    Rabindranath K. Intermittent versus continuous renal replacement therapy for acute renal failure in adults. Cochrane Database Syst Rev. 2007;(3):CD003773.Google Scholar
  38. 38.
    Prowle JR, Bellomo R. Continuous renal replacement therapy: recent advances and future research. Nat Rev Nephrol. 2010;6:521–9.PubMedCrossRefGoogle Scholar
  39. 39.
    The VA/NIH Acute Renal Failure Trial Network. Intensity of renal support in critically ill patients with acute kidney injury. N Engl J Med. 2008;359:7–20.PubMedCentralCrossRefGoogle Scholar
  40. 40.
    Bagshaw SM, Bellomo R, Devarajan P, Johnson C, Karvellas CJ, Kutsiogiannis DJ, Mehta R, Pannu N, Romanovsky A, Sheinfeld G, Taylor S, Zappitelli M, Gibney RT. Review article: renal support in critical illness. Can J Anaesth. 2010;57:999–1013.PubMedCrossRefGoogle Scholar
  41. 41.
    Ronco C, Ricci Z. Renal replacement therapies: physiological review. Intensive Care Med. 2008;34:2139–46.PubMedCrossRefGoogle Scholar
  42. 42.
    Palevsky PM, Zhang JH, O’Connor TZ, et al. Intensity of renal support in critically ill patients with acute kidney injury.VA/NIH Acute Renal Failure Trial Network. N Engl J Med. 2009;361(24):2391.Google Scholar
  43. 43.
    Bellomo R, Cass A, Cole L, Finfer S, Gallagher M, Lo S, McArthur C, McGuinness S, Myburgh J, Norton R, Scheinkestel C, Su S. Intensity of continuous renal-replacement therapy in critically ill patients. N Engl J Med. 2009;361:1627–38.PubMedCrossRefGoogle Scholar
  44. 44.
    Uchino S, Kellum JA, et al. Acute renal failure in critically ill patients: a multinational, multicenter study. J Am Med Assoc. 2005;294:813–8.CrossRefGoogle Scholar
  45. 45.
    Xue JL, Daniels F, Star RA, et al. Incidence and mortality of acute renal failure in medicare beneficiaries, 1992 to 2001. J Am Soc Nephrol. 2006;17:1135–42.PubMedCrossRefGoogle Scholar
  46. 46.
    Garg AX, Suri RS, Barrowman N, et al. Long-term renal prognosis of diarrhea associated hemolytic uremic syndrome: a systematic review, meta-analysis, and meta-regression. JAMA. 2003;290:1360–70.PubMedCrossRefGoogle Scholar
  47. 47.
    Coca SG. Chronic kidney disease after acute kidney injury: a systematic review and meta-analysis. Kidney Int. 2012;81:442–8.PubMedCentralPubMedCrossRefGoogle Scholar
  48. 48.
    Chawla LS, Amdur RL, Amodeo S, et al. The severity of acute kidney injury predicts progression to chronic kidney disease. Kidney Int. 2011;79:1361–9.PubMedCentralPubMedCrossRefGoogle Scholar
  49. 49.
    Wall SM, Johansen MJ, Molony DA, et al. Effective clearance of methotrexate using high-flux hemodialysis membranes. Am J Kidney Dis. 1996;28(6):846–54.Google Scholar
  50. 50.
    Cruz DN, Goh CY, Marenzu G, et al. Renal replacement therapies for prevention of radiocontrast-induced nephropathy: a systematic review. Am J Med. 2012;125(1):66–78.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag London 2014

Authors and Affiliations

  • Yogita Aggarwal
    • 1
  • Mark Harber
    • 2
  • Christopher M. Laing
    • 3
  1. 1.Renal DepartmentRoyal Free HospitalHampstead, LondonUK
  2. 2.UCL Department of NephrologyRoyal Free London NHS Foundation TrustHampstead, LondonUK
  3. 3.UCL Centre for NephrologyRoyal Free London NHS Foundation Trust and University College London HospitalsLondonUK

Personalised recommendations